

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 5 :</b> <b>A61K 39/04</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 91/02542</b> <b>(43) International Publication Date:</b> 7 March 1991 (07.03.91)
<b>(21) International Application Number:</b> PCT/GB90/01318 <b>(22) International Filing Date:</b> 24 August 1990 (24.08.90)  <b>(30) Priority data:</b> 8919321.3                      25 August 1989 (25.08.89)                      GB  <b>(71) Applicant (for all designated States except US):</b> UNIVERSITY COLLEGE LONDON [GB/GB]; 5 Gower Street, London WC1E 6HA (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> STANFORD, John, Lawson [GB/GB]; Millhouse, Claygate, Marden, Kent TN12 9TE (GB). ROOK, Graham, Arthur, William [GB/GB]; Old Hall, Old Hall Road, Steeple Bumpstead, Haver Hill, Suffolk CB9 7EJ (GB).		<b>(74) Agents:</b> COLLIER, Jeremy, Austin, Grey et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).  <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FI, FR (European patent), GB, GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent), US.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> TREATMENT OF CHRONIC INFLAMMATORY CONDITIONS  <b>(57) Abstract</b>  The invention relates to the use of antigenic and/or immunoregulatory material derived from <i>Mycobacterium vaccae</i> for use in the manufacture of a therapeutic agent for the treatment of pathological condition (other than tuberculosis, leprosy or rheumatoid arthritis) in a patient in which the patient's IgG shows an abnormally high proportion of agalactosyl IgG or in the treatment of a chronic inflammatory disorder (other than rheumatoid arthritis) caused or accompanied by an abnormally high release by macrophages of interleukin-6 and/or tumour necrosis factor.		

### DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### *FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany	LU	Luxembourg	TD	Chad
DK	Denmark			TC	Togo
				US	United States of America

-1-

TREATMENT OF CHRONIC INFLAMMATORY CONDITIONS

This invention relates to the treatment of chronic inflammatory conditions, e.g. psoriasis.

British Specification No. 2156673 describes immunotherapeutic agents comprising killed cells of

5 Mycobacterium vaccae. These agents are useful in the immunotherapy of mycobacterial disease, especially tuberculosis and leprosy. It is stated that use of this immunotherapeutic agent facilitates the removal of the persisting bacilli responsible for tuberculosis or leprosy

10 which, as is well known, it is difficult to remove by chemotherapy alone. It is suggested in the specification that the immunotherapeutic agent is believed to act by presenting the "protective" common mycobacterial antigens to advantage and by containing immune suppressor determinants

15 which are active in regulating disadvantageous immune mechanisms. As a consequence, "persister" bacilli are recognized by the immune system by their content of common mycobacterial antigens and effective immune mechanisms are directed against them, in the absence of the tissue necrotic

20 form of immunity usually present in mycobacterial disease.

International Patent Specification PCT/GB 85/00183 describes compositions for the alleviation of the symptoms of, and for the treatment or diagnosis of, arthritic diseases which comprise as active ingredient the whole

25 organism of M. vaccae. It is stated that the preparations

- 2 -

of M. vaccae are useful for the treatment of various autoimmune diseases and especially arthritic conditions including rheumatoid arthritis, ankylosing spondylitis or Reiter's syndrome.

5           We have now discovered that compositions comprising antigenic and immunoregulatory material derived from Mycobacterium vaccae are generally useful in the treatment of pathological conditions in which the proportion of agalactosyl IgG (i.e. IgG which lacks terminal galactose  
10 from the N-linked oligosaccharides on the heavy chains) is increased. Diseases of this kind include not only the rheumatoid arthritis, tuberculosis and leprosy mentioned in the specifications referred to above, but also Crohn's disease and reactive arthritis. Other diseases in which  
15 this may play a part but in which an increased level of agalactosyl IgG is not easily detectable by current methods include primary biliary cirrhosis, sarcoidosis, ulcerative colitis, psoriasis, systemic lupus erythematosus (especially when accompanied by Sjogren's syndrome), multiple sclerosis,  
20 Guillain-Barré syndrome, primary diabetes mellitus, and perhaps some aspects of graft rejection.

Such diseases may also be described as that class of chronic inflammatory disorder which is caused by, or accompanied by, abnormally high cytokine release by  
25 macrophages of interleukin-6 and/or tumour necrosis factor

- 3 -

(cachectin). The specific conditions involved are, of course, the same as those already named.

The present invention accordingly provides a method for the treatment of a pathological condition (other than the tuberculosis, leprosy and rheumatoid arthritis mentioned in the specifications referred to above) in a patient in which the patient's IgG shows an abnormally high proportion of agalactosyl IgG which comprises administering to the patient suffering from such a condition an effective amount of a therapeutic composition comprising antigenic and immunoregulatory material derived from Mycobacterium vaccae.

The invention also provides a method for the treatment of a chronic inflammatory disorder (other than rheumatoid arthritis) caused or accompanied by an abnormally high release from macrophages of interleukin-6 and/or tumour necrosis factor which comprises administering to a patient suffering from such a disorder an effective amount of the said therapeutic agent.

The invention further provides antigenic and immunoregulatory material derived from M. vaccae for use in the manufacture of a therapeutic agent for the treatment of pathological conditions (other than tuberculosis, leprosy or rheumatoid arthritis) in a patient whose IgG shows an abnormally high proportion of agalactosyl IgG. Such antigenic and immunoregulatory material is also provided for use in the manufacture of a therapeutic agent for use in the treatment of a chronic inflammatory disorder (other than

rheumatoid arthritis) of the kind mentioned above.

The therapeutic agent of the invention conveniently, and therefore preferably, comprises dead cells of M. vaccae, most preferably cells which have been killed by autoclaving  
5 or by irradiation. The therapeutic agent normally comprises more than  $10^8$  microorganisms per ml of diluent, and preferably from  $10^8$  to  $10^{11}$  killed M. vaccae microorganisms per ml of diluent.

The diluent may be pyrogen-free saline for injection  
10 alone, or a borate buffer of pH 8.0. The diluent should be sterile. A suitable borate buffer is:

	$\text{Na}_2\text{B}_4\text{O}_7 \cdot 10\text{H}_2\text{O}$	3.63 g
	$\text{H}_3\text{BO}_3$	5.25 g
15	NaCl	6.19 g
	Tween 80	0.0005%
	Distilled Water	to 1 litre

The preferred strain of M. vaccae is one denoted  
20 R877R isolated from mud samples from the Lango district of Central Uganda (J.L. Stanford and R.C. Paul, Ann. Soc. Belge Med, Trop. 1973, 53 141-389). The strain is a stable rough variant and belongs to the aurum sub-species. It can be identified as belonging to M. vaccae by biochemical and  
25 antigenic criteria (R. Bonicke, S.E. Juhasz., Zentr albl. Bakteriол. Parasitenkd. Infection skr. Hyg. Abt. 1, Orig., 1964, 192, 133).

The strain denoted R877R has been deposited under the Budapest Convention at the National Collection of Type Cultures (NCTC) Central Public Health Laboratory, Colindale Avenue, London NW9 5HT, United Kingdom on February 13th, 5 1984 under the number NCTC 11659.

For the preparation of the therapeutic agent, the microorganism M. vaccae may be grown on a suitable solid medium. A modified Sauton's liquid medium is preferred (S.V. Boyden and E. Sorkin., J. Immunol, 1955 75, 15) 10 solidified with agar. Preferably the solid medium contains 1.3% agar. The medium inoculated with the microorganisms is incubated aerobically to enable growth of the microorganisms to take place, generally at 32°C for 10 days. The organisms are harvested, then weighed and suspended in a diluent. The 15 diluent may be unbuffered saline but is preferably borate-buffered and contains a surfactant such as Tween 80 as described above. The suspension is diluted to give 100 mg of microorganism/ml. For further dilution, borate buffered saline is preferably used so that the suspension contains 10 20 mg wet weight of microorganisms/ml of diluent. The suspension may then be dispensed into 5 ml multidose vials. Although the microorganisms in the vials may be killed using irradiation e.g. from <sup>60</sup>Cobalt at a dose of 2.5 megarads, or by any other means, for example chemically, it is preferred 25 to kill the microorganisms by autoclaving, for example at 10 psi (69 kPa) for 10 minutes (115°C-125°C). It has been discovered, unexpectedly, that autoclaving yields a more

- 6 -

effective preparation than irradiation.

The therapeutic agent is in general administered by injection in a volume in the range 0.1-0.2 ml, preferably 0.1 ml, given intradermally. A single dosage will generally  
5 contain from  $10^7$  to  $10^{10}$  killed M. vaccae microorganisms. It is preferred to administer to patients a single dose containing  $10^8$  to  $10^9$  killed M. vaccae. However, the dose may be repeated depending on the condition of the patient.

While the present invention does not depend on the  
10 truth of this theory it is believed that the active ingredient in the killed M. vaccae may be the 65 kDa mycobacterial heat shock protein (hsp 65) described by Young et al. "Stress proteins are immune targets in leprosy and tuberculosis", Proc. Natl. Acad. Sci. U.S.A. 85 (1988),  
15 pp4267-4270 in a form obtained from M. bovis. The preferred autoclaved M. vaccae cells used in the present invention are believed to provide an effective package of the hsp 65 and other substances in a convenient adjuvant.

Although the therapeutic agent will generally be  
20 administered by intradermal injection, other routes, e.g. oral administration, can also be used.

It may be advantageous and is within the scope of the invention to use more than one strain of M. vaccae, and/or to include in the immunoprophylactic agent other  
25 mycobacterial antigens. Tuberculin may also be included.

The immunoprophylactic agent may also contain BCG (Bacillus Calmette-Guerin) vaccine, in particular the



- 7 -

freeze-fried form of the vaccine, to promote its effect.

The therapeutic agent can contain further ingredients such as adjuvants, preservatives, stabilisers etc. It may be supplied in sterile injectable liquid form or in sterile freeze-fried form which is reconstituted prior to use.

M. vaccae may be used as such or as an extract or fractioned portion of the organism to manufacture the therapeutic agents according to the invention.

10 The following Example illustrates the invention.

EXAMPLE

M. vaccae NCTC 11659 is grown on a solid medium comprising modified Sauton's medium solidified with 1.3% agar. The medium is inoculated with the microorganism and 15 incubated for 10 days at 32°C to enable growth of the microorganism to take place. The microorganisms are then harvested by gently scraping the surface of the agar and weighed (without drying) and suspended in M/15 borate buffered saline at pH8 to give 10 mg of microorganisms/ml of 20 saline. The suspension is dispensed into 5 ml vials, and then autoclaved for 10 minutes at 10 psi (69 kPa) to kill the microorganisms. After cooling, 1/10th volume of tuberculin (at the standard concentration of 2 µg/ml) is added. The therapeutic agent thus produced is stored at 25 44°C before use. A single dose consists of 0.1 ml of the suspension, which should be shaken vigorously immediately

- 8 -

before use, containing 1 mg wet weight of M. vaccae and 0.02  $\mu$ g of tuberculin. The dose is given by intradermal injection normally over the left deltoid muscle.

Only one dose is normally required. The patient  
5 should not receive high dose steroids or other immuno-suppressive therapy. Up to six months may elapse before the beneficial effect becomes apparent.

- 9 -

CLAIMS

1. Use of antigenic and/or immunoregulatory material derived from Mycobacterium vaccae for use in the manufacture of a therapeutic agent for the treatment of  
5 pathological conditions (other than tuberculosis, leprosy or rheumatoid arthritis) in a patient in which the patient's IgG shows an abnormally high proportion of agalactosyl IgG or in the treatment of a chronic inflammatory disorder (other than rheumatoid arthritis) caused or accompanied by  
10 an abnormally high release by macrophages of interleukin-6 and/or tumour necrosis factor.

2. The use according to claim 1, wherein the antigenic and/or immunoregulatory material derived from M. vaccae comprises dead cells of M. vaccae.

15 3. The use according to claim 2, wherein the cells of M. vaccae have been killed by autoclaving.

4. The use according to claim 1, wherein the antigenic and/or immunoregulatory material derived for M. vaccae comprises the 65 kDa heat shock protein.

20 5. The use according to any one of the preceding claims, wherein the material derived from M. vaccae is derived from the strain as deposited at the National Collection of Type Cultures (NCTC) Central Public Health Laboratory, Colindale Avenue, London NW9 5HT, United  
25 Kingdom on February 13th, 1984 under the number NCTC 11659.

6. The use according to any one of the preceding claims, wherein the therapeutic agent contains,

- 10 -

per dose, antigenic and/or immunoregulatory material from  $10^7$  to  $10^{10}$  M. vaccae microorganisms.

7. A method for the treatment of a pathological condition (other than tuberculosis, leprosy and  
5 theumatoid arthritis) in a patient in which the patient's IgG shows an abnormally high proportion of agalactosyl IgG or for the treatment of a chronic inflammatory disorder (other than rheumatoid arthritis) caused or accompanied by an abnormally high release from macrophages of interleukin-6  
10 and/or tumour necrosis factor, which comprises administering to the patient suffering from such a condition an effective amount immunoregulatory material derived from Mycobacterium vaccae.

8. A method according to claim 7, wherein  
15 the material derived from M. vaccae is as defined in any one of claims 2 to 6.

9. Products comprising antigenic and/or immunoregulatory material derived from Mycobacterium vaccae for use in treatment of a pathological condition (other than  
20 tuberculosis, leprosy and theumatoid arthritis) in a patient in which the patient's IgG shows an abnormally high proportion of agalactosyl IgG or for the treatment of a chronic inflammatory disorder (other than rheumatoid arthritis) caused or accompanied by an abnormally high  
25 release from macrophages of interleukin-6 and/or tumour necrosis factor.

- 11 -


10. Products according to claim 9, wherein the material derived from M. vaccae is as defined in any one of claims 2 to 6.

11. A pharmaceutical agent for use in the  
5 treatment of a pathological condition (other than tuberculosis, leprosy and rheumatoid arthritis) in a patient in which the patient's IgG shows an abnormally high proportion of agalactosyl IgG or for the treatment of a  
chronic inflammatory disorder (other than rheumatoid  
10 arthritis) caused or accompanied by an abnormally high release from macrophages of interleukin-6 and/or tumour necrosis factor, which agent comprises antigenic and/or immunoregulatory material derived from Mycobacterium vaccae.

12. An agent according to claim 11, wherein  
15 the material derived from M. vaccae is as defined in any one of claims 2 to 6.

# INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 90/01318

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC <sup>5</sup> : A 61 K 39/04		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
IPC <sup>5</sup>	A 61 K, C 07 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>8</sup></b>		
Category *	Citation of Document, <sup>11</sup> with Indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
A	WO, A, 85/05034 (UNIVERSITY COLLEGE LONDON) 21 November 1985 see the whole document  --	1-6,9-12
A	WO, A, 85/03639 (UNIVERSITY COLLEGE LONDON) 29 August 1985 see the whole document  --	1-6,9-12
A	EP, A, 0262710 (DE STAAT DER NEDERLANDEN) 6 April 1988 see the whole document  --	1-6,9-12
A	EP, A, 0322990 (DE STAAT DER NEDERLANDEN) 5 July 1989 see the whole document  -- ./.	1-6,9-12
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: <sup>14</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search 14th November 1990		Date of Mailing of this International Search Report 18.12.90
International Searching Authority  EUROPEAN PATENT OFFICE		Signature of Authorized Officer Miss T. MORTENSEN 

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

A

EP, A, 0045237 (BERRI BALZAC)  
3 February 1982  
see the whole document

-----

1-6,9-12

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>1</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 7-8, because they relate to subject matter not required to be searched by this Authority, namely:  
see rule PCT 39.1 (iv):  
Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2. ☐ Claim numbers \_\_\_\_\_, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers \_\_\_\_\_, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 5.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>2</sup>

This international Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9001318

SA 39696

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 11/12/90. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 8505034	21-11-85	AU-B- 588809	28-09-89
		AU-A- 4297685	28-11-85
		EP-A, B 0181364	21-05-86
		JP-T- 61502258	09-10-86
		US-A- 4716038	29-12-87
WO-A- 8503639	29-08-85	AU-A- 3938885	10-09-85
		EP-A- 0172212	26-02-86
		GB-A, B 2156673	16-10-85
		US-A- 4724144	09-02-88
EP-A- 0262710	06-04-88	NL-A- 8602270	05-04-88
		NL-A- 8701163	05-04-88
		AU-B- 601765	20-09-90
		AU-A- 7800087	17-03-88
		JP-A- 63126895	30-05-88
		ZA-A- 8706738	14-03-88
EP-A- 0322990	05-07-89	NL-A- 8703107	17-07-89
		AU-A- 2732788	22-06-89
		JP-A- 2000797	05-01-90
EP-A- 0045237	03-02-82	FR-A, B 2487198	29-01-82
		AT-T- E8146	15-07-84
		JP-A- 57140792	31-08-82
		US-A- 4404194	13-09-83

EPO FORM P4479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82